Skip to main content
. 2018 Aug 23;3(16):e121522. doi: 10.1172/jci.insight.121522

Figure 2. Expression of πERVs defines subtypes with differential immune checkpoint activation in ccRCC (KIRC).

Figure 2

(A) Hierarchical clustering of tumors from TCGA (columns) by expression (percentile) of πERVs (rows) stratifies tumors into 3 subtypes (high [H], intermediate [I], and low [L]). (B) Frequency of VHL, PBRM1, SETD2, and BAP1 mutations (dark, truncating mutations; light, other nonsynonymous mutations) in the 3 subtypes. Comparison of (C) overall immune infiltration in tumors (“ImmuneScore”) and fractional composition of tumor-infiltrating leukocytes and (D) mRNA expression of CD8A (cytotoxic T cell marker) and immune checkpoint genes between πERV-high and πERV-low subtypes. Number of samples: (C) ImmuneScore (119 H, 228 L), all other categories (90 H, 134 L), (D) 119 H and 228 L. P values reported in bar plots and box plots are from Fisher’s exact test and Wilcoxon rank-sum test, respectively (all 2 sided). *P < 0.05, **P < 10–3, ***P < 10–6.